Loading the section…
The price of Veracyte, Inc. (VCYT) on October 9, 2026 is 45.23 USD, +3.74% on the day. Over 52 weeks the stock traded between 29.45 USD and 60.91 USD; the price now sits 50% of the way up that range. Over the past year the price changed by +28.86%. The P/E ratio is 41.0, which is above the sector median (25.0). Market capitalization is 3.61 billion USD, rank 8 among 23 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +32.68 %
Veracyte, Inc. trades on Nasdaq under the ticker VCYT. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks VCYT has traded between 29.46 $ and 60.91 $. As of 9 October 2026 the price stood 50.15 % of the way from the 52-week low to the high.
Over one year VCYT shares rose 28.86 %; over six months they rose 45.48 %. Volatility over 90 days is 67.62 %. Dividends are not included: this is price change only, as of 9 October 2026.
VCYT trades at a price-to-earnings ratio of 41.0, above the sector median of 25.0. Price to sales is 6.7, above the sector median of 4.0. Price to book is 2.7, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 43.71 | 46.17 | 43.50 | 45.23 | 966,500 |
| 8 October 2026 | 42.50 | 43.67 | 41.22 | 43.60 | 1M |
| 7 October 2026 | 44.04 | 44.21 | 42.34 | 43.16 | 1M |
| 6 October 2026 | 48.00 | 48.84 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Veracyte, Inc. (VCYT) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 541.7m $, net income was 88.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080, US
Veracyte, Inc. reported revenue of 542M $ and net income of 88M $ over the last four quarters. Net margin is 16.25 %. Revenue changed by +16.91 % year over year. Earnings per share are 1.08 $. Market capitalisation is 3.6B $.
VCYT has a return on equity of 6.55 %, above the sector median of −41.68 %. Return on assets is 6.13 %, above the sector median of −32.11 %. Operating margin is 14.31 %, above the sector median of −26.84 %.
| 245M |
| CAICaris Life Sciences, Inc. | 29.70 | +8.00 % | 141M |
| GRALGRAIL, Inc. | 140.58 | +6.01 % | 139M |
| CELCCelcuity Inc. | 67.94 | +0.10 % | 92M |
| CDNACareDx, Inc. | 63.67 | +2.36 % | 79M |
| 44.09 |
| 44.65 |
| 2M |
| 5 October 2026 | 45.75 | 47.79 | 45.00 | 47.67 | 1M |
| 2 October 2026 | 44.94 | 46.09 | 44.41 | 45.81 | 1M |
| 1 October 2026 | 45.66 | 47.14 | 44.18 | 44.19 | 1M |
| 30 September 2026 | 45.93 | 46.78 | 45.60 | 46.04 | 1M |
| 29 September 2026 | 46.00 | 47.52 | 45.21 | 46.08 | 2M |
| 28 September 2026 | 45.04 | 47.52 | 44.47 | 45.23 | 2M |
| 25 September 2026 | 49.00 | 49.00 | 45.36 | 45.43 | 2M |
| 24 September 2026 | 43.66 | 48.95 | 43.51 | 48.54 | 3M |
| 23 September 2026 | 42.95 | 43.86 | 42.25 | 43.82 | 2M |
| 22 September 2026 | 41.76 | 43.74 | 41.32 | 43.36 | 1M |
| 21 September 2026 | 40.00 | 41.98 | 39.40 | 41.52 | 1M |
| 18 September 2026 | 40.41 | 41.05 | 39.55 | 39.80 | 3M |
| 17 September 2026 | 39.67 | 40.70 | 38.80 | 40.57 | 1M |
| 16 September 2026 | 40.36 | 41.45 | 38.25 | 38.50 | 2M |
| 15 September 2026 | 40.83 | 42.36 | 39.10 | 40.14 | 2M |
| 14 September 2026 | 41.17 | 41.40 | 40.50 | 41.21 | 1M |